There isn't much data from combination of Nexavar and Tivantinib, how would anyone know efficacy is not much better than alone? Obviously some of those you talked to spoke too soon.
Of course success depends on how much better the efficacy is, if not much better, no one is going to use it. But if efficacy is significantly better, they will use it. As of safety, I am not worried about the combination. Tivantinib didn't add much safety issue to Tarceva at all.
Personally I'd like to see Tivantinib to be combined with single target kinase like Tarceva, Tivozanib than dirty kinase like Nexavar in more targeted population than broad population. I think that is the direction ARQL is moving to.
News 
Market Data 
Discover 
